Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] The severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.
[BACKGROUND] Adverse events during postoperative adjuvant chemotherapy may reflect prognosis in resectable advanced colorectal cancer.
- 95% CI 0.61-0.98
APA
Kawamura H, Honda M, et al. (2025). Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.. British journal of cancer, 133(11), 1660-1667. https://doi.org/10.1038/s41416-025-03199-8
MLA
Kawamura H, et al.. "Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.." British journal of cancer, vol. 133, no. 11, 2025, pp. 1660-1667.
PMID
40983629 ↗
Abstract 한글 요약
[BACKGROUND] Adverse events during postoperative adjuvant chemotherapy may reflect prognosis in resectable advanced colorectal cancer. This study assessed the association between these events and survival in advanced colorectal cancer patients.
[METHODS] We analysed patient data from four Japanese randomised controlled trials on adjuvant chemotherapy for stage II or III colorectal cancer. Adverse events were defined as the maximum grade within 6 months. The primary outcome was overall survival, analysed using a multivariate-adjusted Cox proportional hazard model.
[RESULTS] A total of 4,046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included. Maximum adverse event grades were: 739 (18%) grade 0, 960 (24%) grade 1, 1511 (37%) grade 2, 779 (19%) grade 3 and 57 (1.4%) grade 4. Compared to grade 0, hazard ratios for overall survival were 0.77 (95% CI, 0.61-0.98) for grade 1, 0.70 (95% CI, 0.56-0.87) for grade 2, 0.69 (95% CI, 0.53-0.91) for grade 3 and 1.12 (95% CI, 0.62-2.04) for grade 4.
[CONCLUSIONS] The severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.
[METHODS] We analysed patient data from four Japanese randomised controlled trials on adjuvant chemotherapy for stage II or III colorectal cancer. Adverse events were defined as the maximum grade within 6 months. The primary outcome was overall survival, analysed using a multivariate-adjusted Cox proportional hazard model.
[RESULTS] A total of 4,046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included. Maximum adverse event grades were: 739 (18%) grade 0, 960 (24%) grade 1, 1511 (37%) grade 2, 779 (19%) grade 3 and 57 (1.4%) grade 4. Compared to grade 0, hazard ratios for overall survival were 0.77 (95% CI, 0.61-0.98) for grade 1, 0.70 (95% CI, 0.56-0.87) for grade 2, 0.69 (95% CI, 0.53-0.91) for grade 3 and 1.12 (95% CI, 0.62-2.04) for grade 4.
[CONCLUSIONS] The severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.